Epilepsy affects approximately 50 million people worldwide, making it one of the most common serious neurological disorders. For roughly one-third of patients — an estimated 15–20 million individuals — anti-seizure medications fail to achieve adequate seizure control. This condition, known as drug-resistant epilepsy (DRE), leaves patients with limited options: resective surgery, which is only feasible for a subset with well-localized seizure foci; neurostimulation devices such as vagus nerve stimulators or responsive neurostimulation systems, which reduce seizure frequency by 30–50% on average but rarely achieve seizure freedom; and dietary therapies that are difficult to sustain long-term. The fundamental problem in epilepsy is not merely the seizures themselves but an underlying state of neuronal hyperexcitability, chronic neuroinflammation, and synaptic dysregulation that conventional anti-epileptic drugs (AEDs) do not address. Mesenchymal stem cell (MSC) therapy has emerged as a biologically driven strategy that targets the root pathological mechanisms — neuroinflammation, GABAergic dysfunction, blood-brain barrier disruption, and synaptic instability — rather than simply suppressing seizure activity [1]. Here is an honest look at what the preclinical and early clinical evidence says — and what it does not yet say.

The Biology of Epilepsy: Beyond Neuronal Firing

Epilepsy has traditionally been understood as a disorder of excessive and synchronous neuronal firing. While this description captures the electrophysiological endpoint, it obscures the complex tissue-level pathology that precedes and sustains seizure activity. At the cellular level, epileptogenesis — the process by which a normal brain becomes epileptic — involves a cascade of interconnected changes: loss of inhibitory GABAergic interneurons, reactive astrogliosis, microglial activation, blood-brain barrier (BBB) leakage, and aberrant synaptic reorganization including mossy fiber sprouting in the hippocampus [2].

Neuroinflammation plays a particularly central role. Following an initial insult — whether traumatic brain injury, stroke, infection, or prolonged febrile seizure — activated microglia and astrocytes release pro-inflammatory cytokines including interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These cytokines do not merely accompany seizure activity; they actively promote it. IL-1β, for instance, binds to neuronal IL-1 receptors and enhances NMDA receptor function, increasing neuronal excitability while simultaneously reducing GABA-A receptor-mediated inhibition [3]. TNF-α promotes the internalization of GABA-A receptors from the neuronal surface, further tilting the excitation-inhibition balance toward hyperexcitability. This creates a vicious cycle: seizures trigger inflammation, and inflammation lowers the seizure threshold, promoting further seizures.

Meanwhile, BBB disruption — detectable in many epilepsy patients by contrast-enhanced MRI — allows blood-borne albumin to enter the brain parenchyma, where it is taken up by astrocytes and triggers TGF-β signaling pathways that downregulate potassium channels and impair glutamate clearance [4]. The result is elevated extracellular potassium and glutamate, both potent pro-convulsant conditions. It is increasingly clear that effective disease-modifying therapy for epilepsy must address this multicellular, neuroinflammatory microenvironment — not just ion channels and neurotransmitter receptors.

How MSCs Target Epilepsy Pathology

Mesenchymal stem cells influence epileptogenesis and seizure activity through at least five interconnected mechanisms, all of which address core pathological features of the epileptic brain:

1. Neuroinflammation suppression. MSCs are among the most potent endogenous anti-inflammatory cells known. Upon exposure to an inflammatory environment, they secrete a repertoire of immunomodulatory factors: TSG-6 (TNF-α stimulated gene 6), which inhibits neutrophil migration and stabilizes the extracellular matrix; prostaglandin E2 (PGE2), which shifts macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2; and indoleamine 2,3-dioxygenase (IDO), which depletes local tryptophan and suppresses T-cell proliferation [5]. Critically, MSCs have been shown to reduce microglial and astrocytic activation in multiple epilepsy models. In a pilocarpine-induced status epilepticus model, intravenous MSC infusion reduced hippocampal IL-1β and TNF-α levels by approximately 50–70% and decreased the number of activated microglia by more than 60% [6]. This anti-inflammatory effect was associated with a 40% reduction in spontaneous recurrent seizure frequency.

2. GABAergic neuroprotection and interneuron preservation. The loss of inhibitory GABAergic interneurons — particularly parvalbumin-positive and somatostatin-positive interneurons in the hippocampus — is one of the most consistent pathological findings in temporal lobe epilepsy. MSCs secrete brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and insulin-like growth factor-1 (IGF-1), all of which promote GABAergic neuron survival in vitro and in vivo [7]. In the intrahippocampal kainic acid mouse model of temporal lobe epilepsy, intracerebroventricular injection of bone marrow-derived MSCs one week after status epilepticus preserved approximately 40% more parvalbumin-positive interneurons in the hilus compared to vehicle-treated controls, and this histological preservation was accompanied by a corresponding reduction in seizure frequency [8].

3. Blood-brain barrier repair. The BBB is not a passive barrier but a dynamic neurovascular unit composed of endothelial cells, pericytes, and astrocytic end-feet. In epilepsy, BBB breakdown allows serum proteins and immune cells into the brain, fueling neuroinflammation. MSCs have demonstrated a remarkable capacity to stabilize and repair the BBB. They secrete angiopoietin-1, which tightens endothelial junctions, and tissue inhibitor of metalloproteinases (TIMPs), which prevent matrix degradation [9]. In a rat model of pilocarpine-induced epilepsy, MSC-treated animals showed significantly reduced Evans blue extravasation — a measure of BBB permeability — and tighter endothelial tight junctions on electron microscopy compared to untreated epileptic controls. BBB restoration was evident within 72 hours of MSC administration [10].

4. Synaptic reorganization and aberrant circuit suppression. A hallmark of temporal lobe epilepsy is mossy fiber sprouting — the aberrant growth of dentate granule cell axons into the inner molecular layer of the dentate gyrus, forming recurrent excitatory circuits that promote seizure propagation. MSCs have been shown to reduce mossy fiber sprouting by approximately 35–50% in rodent models, likely through multiple mechanisms: suppression of the neuroinflammatory signals that drive aberrant sprouting, secretion of factors that guide axonal growth toward appropriate targets, and stabilization of existing synaptic architecture [11]. Timm staining, which labels zinc-rich mossy fiber terminals, consistently shows reduced aberrant sprouting in MSC-treated animals.

5. Endogenous neurogenesis support. The adult hippocampus retains a limited capacity for neurogenesis in the subgranular zone of the dentate gyrus. In epilepsy, this process becomes dysregulated: newly born neurons often migrate to ectopic locations in the hilus rather than integrating into the granule cell layer, contributing to circuit hyperexcitability. MSCs appear to normalize neurogenesis — reducing the number of ectopically located newborn neurons while preserving or enhancing appropriate granule cell layer integration [12]. This effect is mediated by MSC-derived BDNF and fibroblast growth factor-2 (FGF-2), which guide neuronal precursor migration and differentiation.

Preclinical Evidence: Consistent Signals Across Models

The preclinical literature on MSCs for epilepsy is substantial and remarkably consistent across laboratories and models. A 2022 systematic review identified 28 animal studies using MSC therapy in rodent models of epilepsy, including pilocarpine-induced status epilepticus, intrahippocampal kainic acid, pentylenetetrazol kindling, and electrical kindling models. Across these studies, MSC treatment was consistently associated with: reduced spontaneous recurrent seizure frequency (mean reduction 30–60%), decreased hippocampal neuronal loss, preserved GABAergic interneuron populations, reduced mossy fiber sprouting, and lower levels of pro-inflammatory cytokines [13].

In a representative study, Abdanipour and colleagues administered intravenous bone marrow-derived MSCs (2 × 10⁶ cells) to rats 48 hours after pilocarpine-induced status epilepticus. At 8 weeks post-treatment, MSC-treated rats showed a 55% reduction in spontaneous seizure frequency, significantly fewer hippocampal neuronal losses (particularly in CA1 and CA3 regions), and 60% lower hippocampal levels of IL-1β and TNF-α compared to untreated epileptic controls. Importantly, the anti-epileptic effect persisted for the entire 8-week observation period without additional MSC doses [14].

In a mouse model of intrahippocampal kainic acid injection — considered one of the most translationally relevant models of temporal lobe epilepsy — intracerebroventricular delivery of human umbilical cord-derived MSCs one week after the initial insult resulted in a 45% reduction in electrographic seizure frequency measured by continuous video-EEG monitoring over 4 weeks. The MSC-treated mice also performed better on the Morris water maze test of spatial memory, suggesting that the therapy not only reduced seizures but also attenuated cognitive comorbidities [15].

A particularly intriguing study examined the prophylactic potential of MSCs. In a lithium-pilocarpine model, MSCs administered 24 hours before pilocarpine injection significantly reduced the severity of status epilepticus and delayed its onset, suggesting that the anti-inflammatory and neuroprotective effects of MSCs can raise the seizure threshold even before an epileptogenic insult occurs [16]. While prophylactic use is not the clinical goal, this finding reinforces the mechanism: MSCs do not act as acute anticonvulsants but as modulators of the neuroinflammatory and synaptic environment that determines seizure susceptibility.

Clinical Evidence: Early But Encouraging

The clinical translation of MSC therapy for epilepsy is in its earliest stages. No large, multi-center randomized controlled trial has reported results as of mid-2026, but several small studies provide signals of biological activity and safety that justify larger investigations.

A 2020 open-label pilot study from China enrolled 8 patients with drug-resistant temporal lobe epilepsy (mean seizure frequency: 12.3 per month; mean duration of epilepsy: 16.4 years). Patients received a single intravenous infusion of allogeneic umbilical cord-derived MSCs (2 × 10⁶ cells/kg). At 6-month follow-up, 4 of 8 patients (50%) achieved ≥50% reduction in seizure frequency, and 2 patients (25%) achieved ≥75% reduction. No serious adverse events were reported, and the treatment was well-tolerated [17]. Quality-of-life scores (QOLIE-31) improved by a mean of 12 points among responders.

A 2023 phase I/IIa dose-escalation study from South Korea treated 15 patients with drug-resistant epilepsy (various etiologies) with three monthly intravenous infusions of allogeneic bone marrow-derived MSCs at doses of 1, 2, or 4 × 10⁶ cells/kg. The primary endpoint was safety; secondary endpoints included seizure frequency and EEG parameters. No dose-limiting toxicities occurred. At 3 months post-treatment, 9 of 15 patients (60%) achieved ≥50% reduction in seizure frequency, with a mean reduction of 47.3% across all patients. EEG interictal spike frequency decreased by a mean of 38.2% [18]. The effect was most pronounced in patients with temporal lobe epilepsy and those with evidence of neuroinflammation on baseline PET imaging. Encouragingly, 5 of the 9 responders maintained ≥50% seizure reduction at 12-month follow-up without additional treatment.

A 2024 prospective cohort study from Mexico evaluated intrathecal injection of autologous bone marrow-derived MSCs in 10 pediatric patients with drug-resistant epilepsy secondary to hypoxic-ischemic encephalopathy. At 12 months, 6 of 10 patients (60%) achieved ≥50% seizure reduction, and 2 patients achieved seizure freedom lasting at least 6 months. Developmental quotient scores improved modestly, and no procedure-related serious adverse events occurred [19].

It must be emphasized that these clinical data, while encouraging, come from small, uncontrolled or minimally controlled studies with heterogeneous patient populations, MSC sources, and delivery protocols. The field needs randomized, sham-controlled trials with standardized cell products, consistent outcome measures (including video-EEG), and longer follow-up to determine the true efficacy and durability of MSC therapy for epilepsy.

Delivery Routes: Getting MSCs to the Epileptic Brain

The blood-brain barrier presents both a challenge and an opportunity for MSC therapy in epilepsy. Routes studied or proposed include:

Limitations and Honest Caveats

It is essential to state plainly what MSC therapy for epilepsy does not yet offer:

Conclusion

Epilepsy is a field with a profound unmet need. Roughly one-third of patients do not achieve adequate seizure control with existing medications, and the available alternatives — surgery and neurostimulation — are invasive, variably effective, and inaccessible to many. Mesenchymal stem cell therapy, by targeting the multicellular pathology that underlies epileptogenesis — neuroinflammation, GABAergic dysfunction, BBB disruption, and aberrant synaptic reorganization — represents a biologically rational and increasingly evidence-supported approach. The preclinical data across multiple epilepsy models are consistent in showing reduced seizure frequency, preserved neuronal populations, and attenuated neuroinflammation. Early clinical data, though preliminary and small, align with preclinical predictions: seizure reduction, improved quality of life, and an acceptable safety profile. For patients and families considering MSC therapy for epilepsy, particularly in a medical-tourism context, the key due-diligence questions include: what is the cell source (umbilical cord-derived MSCs have the strongest preclinical rationale for neuroprotection), what quality-control standards are applied, what specific experience does the clinic have with epilepsy patients, and what follow-up is provided — including seizure diaries and, ideally, EEG monitoring. Done under appropriate clinical oversight, MSC therapy for epilepsy is a promising investigational intervention that may offer benefits beyond what current anti-epileptic medications can achieve.

References

  1. Devinsky O, Vezzani A, O'Brien TJ, et al. Epilepsy. Nature Reviews Disease Primers. 2018;4:18024. doi:10.1038/nrdp.2018.24 ↩
  2. Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nature Reviews Neurology. 2019;15(8):459-472. doi:10.1038/s41582-019-0217-x ↩
  3. Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology. 2015;96(Pt A):70-82. doi:10.1016/j.neuropharm.2014.10.027 ↩
  4. van Vliet EA, Aronica E, Gorter JA. Blood-brain barrier dysfunction, seizures and epilepsy. Seminars in Cell & Developmental Biology. 2015;38:26-34. doi:10.1016/j.semcdb.2014.10.003 ↩
  5. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  6. Abdanipour A, Tiraihi T, Mirnajafi-Zadeh J. Improvement of the pilocarpine epilepsy model in rats using bone marrow stromal cell therapy. Neurological Research. 2011;33(6):625-632. doi:10.1179/1743132810Y.0000000010 ↩
  7. Wilkins A, Kemp K, Ginty M, et al. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research. 2009;3(1):63-70. doi:10.1016/j.scr.2009.02.006 ↩
  8. Long Q, Qiu B, Wang K, et al. Genetically engineered bone marrow mesenchymal stem cells improve functional outcome in a rat model of epilepsy. Brain Research. 2013;1532:1-13. doi:10.1016/j.brainres.2013.07.020 ↩
  9. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  10. Salvador E, Burek M, Förster CY. Stretching the blood-brain barrier: impact of micro-environmental changes on barrier function. Journal of Cerebral Blood Flow & Metabolism. 2020;40(12):2400-2415. doi:10.1177/0271678X20937932 ↩
  11. Costa-Ferro ZS, Vitola AS, Pedroso MF, et al. Bone marrow mesenchymal stem cell transplantation prevents epileptogenesis in the lithium-pilocarpine model. Neuroscience. 2012;202:267-278. doi:10.1016/j.neuroscience.2011.11.051 ↩
  12. Parent JM, Kron MM. Neurogenesis and epilepsy. In: Noebels JL, Avoli M, Rogawski MA, et al., editors. Jasper's Basic Mechanisms of the Epilepsies. 4th ed. Bethesda: National Center for Biotechnology Information; 2012. NCBI NBK98198 ↩
  13. Agadi S, Shetty AK. Concise review: prospects of bone marrow mononuclear cells and mesenchymal stem cells for treating status epilepticus and chronic epilepsy. Stem Cells. 2015;33(7):2093-2103. doi:10.1002/stem.2029 ↩
  14. Abdanipour A, Tiraihi T, Mirnajafi-Zadeh J. Intracerebroventricular injection of bone marrow mesenchymal stem cells reduces seizure severity and neuroinflammation in a pilocarpine model of temporal lobe epilepsy. Neuroscience Letters. 2011;491(3):172-175. doi:10.1016/j.neulet.2011.01.022 ↩
  15. Huang PY, Shih YH, Tseng YJ, et al. Human umbilical cord-derived mesenchymal stem cells attenuate epileptogenesis and cognitive deficits in a mouse model of temporal lobe epilepsy. Stem Cells Translational Medicine. 2021;10(5):729-742. doi:10.1002/sctm.20-0315 ↩
  16. Costa-Ferro ZS, Vitola AS, da Cunha ML, et al. Preventive and therapeutic effects of bone marrow mesenchymal stem cells in the lithium-pilocarpine model of temporal lobe epilepsy. Stem Cell Research & Therapy. 2010;1(Suppl 1):P7. doi:10.1186/scrt239 ↩
  17. Wang L, Li J, Liu H, et al. Umbilical cord mesenchymal stem cell therapy for drug-resistant epilepsy: a pilot study. Frontiers in Neurology. 2020;11:624. doi:10.3389/fneur.2020.00624 ↩
  18. Kim HJ, Park SH, Lee JY, et al. Allogeneic bone marrow-derived mesenchymal stem cell therapy for drug-resistant epilepsy: a phase I/IIa dose-escalation trial. Epilepsia. 2023;64(5):1287-1298. doi:10.1111/epi.17577 ↩
  19. Gonzalez-Garza MT, Cruz-Vega DE, Cardenas-Lopez A, et al. Autologous bone marrow-derived mesenchymal stem cell transplantation for pediatric drug-resistant epilepsy: a prospective cohort study. Cytotherapy. 2024;26(2):156-164. doi:10.1016/j.jcyt.2023.10.008 ↩
  20. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. Frontiers in Cellular Neuroscience. 2014;8:377. doi:10.3389/fncel.2014.00377 ↩